More on ATOS

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (8.3 Score)

Upcoming Events

- Earnings (8/12/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Atossa Therapeutics (NQ:ATOS)
Delayed: 4.53 -0.15 (3.21%)
Prev. Close $4.68  
Open$4.56 
52 Wk High$3.64 
52 Wk Low$0.14 
Day High$4.67 
Day Low$4.44 
P/E N/A  
EPS$0.00 
Volume46,266 

Friends, Peers and Foes (?): AIMD, NB, AEXAY ATO (more...)

Feb 20, 2026 04:22 PM Form 8-K ATOSSA THERAPEUTICS, For: Feb 19
Feb 20, 2026 04:16 PM Form 424B5 ATOSSA THERAPEUTICS,
Feb 20, 2026 04:08 PM Form 424B3 ATOSSA THERAPEUTICS,
Feb 17, 2026 04:32 PM Form 8-K ATOSSA THERAPEUTICS, For: Feb 17
Feb 12, 2026 08:52 AM Atossa Genetics (ATOS) PT Lowered to $10 at Craig-Hallum
Feb 11, 2026 08:46 AM Form 8-K ATOSSA THERAPEUTICS, For: Feb 11
Feb 11, 2026 08:31 AM Atossa Therapeutics outlines 2025 progress and 2026 plans for drug development
Feb 11, 2026 08:30 AM Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
Feb 5, 2026 08:31 AM Atossa maintains eligibility for priority review voucher after program renewal
Feb 5, 2026 08:30 AM Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
View All Articles

Entities mentioned with ATOS

View All Entities